Why the study?
Does nebivolol 5 mg once daily improve blood pressure control and tolerability compared to nifedipine retard 20 mg twice daily in patients with essential hypertension?
Does nebivolol 5 mg once daily improve blood pressure control and tolerability compared to nifedipine retard 20 mg twice daily in patients with essential hypertension?
Nebivolol 5 mg once daily is as effective as nifedipine retard 20 mg twice daily for long-term blood pressure control in essential hypertension, but offers better tolerability.
Answers are grounded in this paper and cite their sources.
Supports nebivolol for faster initial BP control in essential hypertension; confirms long-term equivalence to nifedipine retard without orthostasis.
The efficacy and acceptability of 5 mg nebivolol once daily, a long-acting, vasodilating cardioselective beta blocker that additionally facilitates the L-arginine/nitric oxide system, was assessed in a double-blind, randomized trial in comparison with 20 mg nifedipine retard twice daily in patients with essential hypertension. At 2 weeks of treatment, nebivolol was significantly more effective. Thereafter, both drugs effectively and similarly lowered systolic and diastolic pressures without orthostatic effect. Nebivolol had a trough-to-peak antihypertensive effect ratio of 90%. Nifedipine gave the expected side effects of headache, flushing, and edema. Nebivolol was well tolerated. Nebivolol slightly but significantly lowered heart rate. Neither drug adversely affected plasma levels of lipids.
No takes yet. Share an insight, caveat, or question.
Nueten et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: